Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

Schedule of collaboration revenue

Net product sales consist of the following:

	Three Months Ended March 31,
Net Product Sales in the United States	2019		2018
EYLEA®	$	1,074.1	$	984.0
Libtayo®	26.8		—
ARCALYST®	3.5		3.9
	$	1,104.4	$	987.9

Revenue earned in connection with our Bayer EYLEA collaboration is as follows (note that the table excludes amounts in connection with our Bayer Ang2 antibody and PDGFR-beta antibody collaboration agreements, which were previously terminated):

	Three Months Ended March 31,
Bayer EYLEA Collaboration Revenue	2019		2018
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	249.3	$	232.1
Reimbursement of Regeneron EYLEA development expenses	2.6		3.5
Other	24.3		11.8
	$	276.2	$	247.4

The collaboration revenue we earned from Sanofi is detailed below:

	Three Months Ended March 31,
Sanofi Collaboration Revenue	2019			2018
Antibody:
Reimbursement of Regeneron research and development expenses	$	74.5		$	60.4
Reimbursement of Regeneron commercialization-related expenses	116.6			85.4
Regeneron's share of losses in connection with commercialization of antibodies	(27.8		)	(74.8		)
Other	12.9			17.3
Total Antibody	176.2			88.3
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	46.4			73.8
Reimbursement of Regeneron commercialization-related expenses	2.3			1.2
Other	21.5			26.2
Total Immuno-oncology	70.2			101.2
	$	246.4		$	189.5

Schedule of accounts receivable and deferred revenue information

The following table summarizes accounts receivable and deferred revenue information in connection with the Teva Collaboration Agreement:

	March 31,		December 31,
	2019		2018
Accounts receivable (recorded within Prepaid expenses and other current assets)	$	32.2	$	28.8
Deferred revenue	$	173.3	$	194.5

Significant changes in deferred revenue balances are as follows:

	Three Months Ended March 31, 2019
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(21.2	)

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's IO Collaboration with Sanofi:

	March 31,		December 31,
	2019		2018
Accounts receivable	$	18.6	$	77.9
Deferred revenue	$	665.8	$	289.9

Significant changes in deferred revenue balances are as follows:

	Three Months Ended March 31, 2019
Increase as a result of payment received from Sanofi	$	415.9
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(26.2	)
Revenue recognized that was added to deferred revenue during the period	$	(13.8	)

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's Antibody Collaboration with Sanofi:

	March 31,		December 31,
	2019		2018
Accounts receivable	$	264.4	$	138.2
Deferred revenue	$	302.0	$	236.1

Significant changes in deferred revenue balances are as follows:

	Three Months Ended March 31, 2019
Increase due to shipments of commercial supplies to Sanofi	$	86.0
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(20.1	)